Capstone Therapeutics Corp banner
Financial profile · FY2019

A pre-commercial biotech with episodic licensing receipts and recurring cash burn

The supplied history shows no recurring product-revenue base, while operating costs have generally exceeded revenue and operating cash flow. A disclosed license payment was episodic, leaving operations dependent on external funding rather than a self-funding product business.

What the latest results confirm

The 2019 results maintain the established loss-making, cash-consuming pattern after an isolated positive operating-cash-flow year; no recurring revenue base emerged. This leaves funding, rather than internally generated cash, central to sustaining development and operations.

What matters next

Whether new funding or license-related receipts replenish cash sufficiently to cover operating needs and near-term liabilities.

USD
Metric FY2010 FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 FY2017 FY2018 FY2019
0 0 0 0 0 0 0 0 0
— — — 0 — — — — — —
— — — 0 — — — — — —
(11.4m) (9.9m) (4.2m) (1.7m) (4.5m) (2.9m) (1.6m) (1.7m) (554k) (762k)
(3.2m) (3.5m) (1.8m) (641k) (1.5m) (1.8m) (543k) (641k) (554k) (762k)
R&D
(8.2m) (6.4m) (2.4m) (1m) (3.1m) (1.2m) (1m) (1m) — —
0 0 0 0 — — — — — —
(11.4m) (9.9m) (4.2m) (1.7m) (4.5m) (2.9m) (1.6m) (1.7m) (554k)
360k 30k 100k (111k) (43k) (24k) (81k) (111k) (248k) (261k)
0 0 0 0 — — — — — —
0 0 0 — — — — — — —
(11.1m) (9.9m) (4.1m) (1.8m) (4.6m) (3m) (1.7m) (1.8m) (802k) (1m)
180k 160k 0 19m 400k 192k 56k 19m 49k 24k
(10.9m) (9.7m) (4.1m) 17.2m (4.2m) (2.8m) (1.6m) 17.2m (753k) (999k)
— — 470k 0 0 0 946k 0 0 641k
(10.9m) (9.7m) (3.6m) (1.8m) (4.2m) (2.8m) (663k) (1.8m) (380k)
(7 992.64) (7 139.70) (2 632.35) (1 290.44) (3 063.97) (2 037.49) (487.50) (1 117.83) (209.94)